Voices
Mario Balsa: KRAS Codons Dictate Outcomes in Localized and Advanced Pancreatic Cancer
Mario Balsa/LinkedIn

Mario Balsa: KRAS Codons Dictate Outcomes in Localized and Advanced Pancreatic Cancer

Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X:

“Codon-specific KRAS mutations in localized and advanced PDAC (n=1,032) JCO Precision Oncology.

  • 92% KRAS-mutant: G12D (41%), G12V (32%), G12R (16%).
  • Localized disease: G12V → longer OS vs G12D (P=.03).
  • Metastatic disease: G12V → shorter OS vs G12D & G12R (P=.04).
  • No major differences in TP53/CDKN2A/SMAD4 co-alterations.

It’s not just KRAS…it’s which KRAS!! The codon calls the code.”

Mario Balsa

Title: Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer

Authors: Sara Raji, Hamed Zaribafzadeh, Tyler Jones, Elishama Kanu, Kunling Tong, Ashley Fletcher, T. Clark Howell, Shannon J. McCall, Jeffrey R. Marks, Bruce Rogers, Donna Niedzwiecki, Peter J. Allen, Daniel P. Nussbaum, Zahra Kabiri

Read The Full Article

Mario Balsa

Other articles about KRAS on OncoDaily.

Ashley Fletcher Bruce Rogers cancer Daniel P. Nussbaum Donna Niedzwiecki Elishama Kanu Hamed Zaribafzadeh JCO Jeffrey R. Marks KRAS Kunling Tong Mario Balsa OncoDaily Oncology Peter J. Allen Sara Raji Shannon J. McCall T. Clark Howell Tyler Jones Zahra Kabiri